Indivior reported third quarter 2026 results that exceeded consensus expectations on both revenue and earnings, driven by record performance of its long-acting injectable treatment, SUBLOCADE. The company confirmed it is on track to close its merger with Supernus on November 2, 2026, transitioning to a combined entity trading under the symbol SUPN.
Key Highlights
- Total net revenue reached $356 million, a 13% year-over-year increase that beat the analyst estimate of $326.7 million.
- SUBLOCADE net revenue hit a record $267 million, up 22% year-over-year, supported by 17% growth in U.S. dispense unit volume.
- Non-GAAP diluted EPS of $1.32 significantly outperformed the $0.93 estimate as adjusted EBITDA margins expanded 2,100 basis points to 59%.